Background Several epidemiological studies have shown an inverse relation between high-density lipoprotein (HDL) cholesterol levels and coronary heart disease. Recently, observational studies have suggested a similar inverse relation between HDL and restenosis after coronary balloon angioplasty. Despite these observations, it is unclear whether this inverse relation reflects a direct vascular protective effect of HDL or apolipoprotein (apo) A-I, the major apolipoprotein component of HDL. Therefore, to determine whether HDL directly influences neointima formation, we investigated the effect of recombinant apo A-I Milano (apo A-I M), a mutant of human apo A-I with Arg-173 to Cys substitution, on intimal thickening after balloon injury in cholesterol-fed rabbits.
Methods and Results Cholesterol feeding was initiated 18 days before injury and continued until the time of death. Eight rabbits received intravenous injections of 40 mg of apo A-I M linked to a phospholipid carrier on alternate days, beginning 5 days before and continuing for 5 days after balloon injury of femoral and iliac arteries. Eight rabbits received the carrier alone, and four received neither apo A-I M nor the carrier. Three weeks after balloon injury, apo A-I M-treated rabbits had significantly reduced intimal thickness compared with the everal epidemiological studies have shown that the plasma concentration of high-density lipoprotein (HDL) is inversely correlated with the incidence of coronary artery disease.1-3 A similar inverse relation has been demonstrated for the plasma level of apolipoprotein A-I (apo A-I), the major protein component of HDL. 4 Recently, a similar inverse relation has been described between the plasma level of HDL and restenosis rate after coronary balloon angioplasty. 5, 6 The HDL molecule contains two major apoproteins: apo A-I and apo A-II. Immunochromatography has revealed the existence of two HDL subclasses: one containing apo A-I and the other containing both apo A-I and apo two control groups (mean±SD): 0.49±0.29 versus 1.14±0.38 mm2 and 1.69±0.43 mm2, P<.002 by ANOVA). The intimato-media ratio was also significantly reduced by apo A-I M (0.7±0.2 versus 1.5±0.5 and 2.1±0.1, P<.002 by ANOVA) compared with the two controls. The fraction of intimal lesion covered by macrophages, as identified by immunohistochemistry using macrophage-specific monoclonal antibody, was significantly less in apo A-I M-treated rabbits compared with carrier-treated animals (25.3±17% versus 59.4±12.3%, P<.005). Aortic cholesterol content, measured in an additional 10 rabbits, did not differ significantly between apo A-I M-treated animals (n=5) and carrier-treated controls (n=5).
Conclusions Apo A-I M significantly reduced intimal thickening and macrophage content after balloon injury in cholesterol-fed rabbits without a change in arterial total cholesterol content. Although the precise mechanism of action remains to be defined, these findings are consistent with a direct vascular effect of apo A-I, which could have potential therapeutic implications. (Circulation. 1994; 90:1935 -1941 A-II.7 It is only the apo A-I-containing HDL subclass that is reduced in patients with premature coronary artery disease.4 Whether HDL or apo A-I is a marker for other risk factors for atherosclerosis or has a direct vascular protective effect is not entirely clear. Nevertheless, studies of transgenic animals that overexpress human apo A-I or apo A-II have suggested that elevated levels of apo A-I are antiatherogenic, whereas elevated levels of apo A-Il are proatherogenic.89 Similarly, a reduction in the magnitude of intimal lesions and regression of preexisting lesions in rabbits after administration of homologous HDL suggests a direct vascular protective effect of HDL. 10 11 In 1980, a familial lipoprotein disorder characterized by a remarkable absence of atherosclerotic vascular disease despite markedly reduced plasma levels of HDL cholesterol was described in a family from Limone sul Garda in Northern Italy.12 Subsequent studies have mutant allele and have very low levels of HDL, virtually no HDL2, reduced apo A-I levels, and a high incidence of elevated triglyceride levels without an increased incidence of vascular disease.12'13 The apo A-I M has a shortened residence time with more rapid catabolism, and its presence also accelerates the catabolism of apo A-I, accounting for its reduced blood level in subjects with the mutation.14 The substitution of cysteine for arginine appears to substantially alter the amphipathic nature of the a-helical fragment of apo A-I, increasing exposure of its hydrophobic residues.'5 This structural modification is associated with a higher kinetic affinity of apo A-I M for lipids and an easier dissociation from lipid-protein complexes, which could contribute to its accelerated catabolism and increased efficiency for uptake of tissue lipids.'5 Although the exact mechanism by which the apo A-I M mutation confers relative protection against vascular disease remains to be fully defined, its enhanced efficacy in removing cholesterol from tissues could be one such mechanism. 15 The gene for apo A-I M has been cloned, and a genetically engineered version of the mutant protein is available for investigation.
In the present study, we tested the hypothesis that administration of recombinant apo A-I M would reduce intimal thickening after balloon injury in cholesterol-fed rabbits.
Methods
Twenty male New Zealand White rabbits weighing 3 to 4 kg were housed individually at an animal facility accredited by the American Association of Accreditation of Laboratory Animal Care under conditions of 12-hour light/dark periods. The protocol was approved by the Institutional Animal Care and Use Committee of Cedars-Sinai Medical Center. The rabbits were fed standard chow supplemented with 1% cholesterol and 3% peanut oil during the entire study period. Eighteen days after initiation of the cholesterol-rich diet, eight rabbits received an intravenous injection of 40 mg of apo A-I M contained in a carrier of phosphatidylcholine-choline complex (dissolved in 10 mL of saline) in the left marginal ear vein every other day during a 10-day period. Eight other rabbits received the carrier phosphatidylcholine-choline complex without apo A-I M, and four received no treatment. Recombinant apo A-I M used in this was supplied by Pharmacia Therapeutics, where it was produced using an inducible Escherichia coli expression system in which the product was secreted into the culture medium, mostly in its dimeric form. After fermentation, the filtered medium was purified by a number of chromatographic techniques using matrixes such as Q-Sepharose FF, phenyl Sepharose FF, and Superdex 200 to separate dimeric and monomeric forms of the protein. Concentration and buffer exchanges were performed using ultrafiltration technique. The purified material was analyzed with respect to endotoxin level, identity, purity, and concentration. Final formulation of the protein as a phosphatidylcholineprotein complex was performed by dissolving phosphatidylcholine in cholate and then adding the protein solution. Cholate was then removed by dialysis.
Balloon injury was performed 4 days after the start of injections of apo A-I M or its carrier. Before balloon injury, all animals were anesthetized with ketamine (35 mg/kg body wt) and xylazine (5 mg/kg body wt). With standard sterile technique, a right carotid artery cutdown was performed, an intravenous injection of 1000 U heparin was given, and a 2.5-mm angioplasty catheter was introduced with a guidewire (high torque-floppy 0.014). Under fluoroscopic guidance, the catheter was advanced through the aorta to the femoral or iliac artery. The balloon was then inflated to a constant pressure of 8 atm for 1 minute. This step was repeated with a 1-minute interval, at the end of which the inflated balloon was retracted to the bifurcation of common iliac arteries and deflated. The catheter and wire were removed, the right carotid artery was ligated, and the overlying skin was sutured. In the animals receiving apo A-I M or its carrier, the balloon injury was performed after the second injection. All animals were returned to their housing fully awake, and routine postoperative care and follow-up were instituted. Cholesterol feeding was continued until death. Three weeks after the injury, the animals were anesthetized as described and exsanguinated while the arteries were perfusion-fixed with 0.9% normal saline followed by 4% paraformaldehyde in 0.1 mol/L phosphate-buffered saline (PBS) (pH 7.2) under a constant pressure of 150 cm H2O for 20 minutes. The iliac and femoral arteries were removed and immersed in 4% paraformaldehyde for 3 hours and then transferred to a solution of 15% sucrose in PBS and stored overnight at 4TC. Three 0.5-mm sections of the iliac and femoral arteries were mounted on OTC medium for cryosectioning.
To determine the effect of apo A-I M on tissue cholesterol content, 10 additional rabbits were fed a cholesterol-rich diet for 4 weeks. During the last 10 days of cholesterol feeding, five rabbits received alternate-day injections of 40 mg of apo A-I M in phosphatidylcholine-choline complex, whereas the remaining five rabbits received only the carrier without apo A-I M. Aortas from these additional rabbits were removed, dried, weighed, and kept frozen at -70°C until processing for tissue cholesterol measurements.
Plasma and Aortic Tissue Cholesterol Measurement
Blood samples were taken from the peripheral ear artery of each animal before initiation of cholesterol supplementation as well as on the days of injury and death. The samples were centrifuged at 1400g for 10 minutes, and the supernatant was collected. Total serum cholesterol was determined by enzymatic technique, and serum HDL cholesterol was measured after precipitation of apo B-containing lipoproteins with phosphotungstic acid. Aortic tissue samples were homogenized in 50 mL of ice-cold methanol using a tissue homogenizer. Tissue cholesterol was then extracted in chloroform as described by Folch et al. 16 After evaporation, the material was dissolved in 4 mL of isopropanol, and the cholesterol content was determined as described by Zlatkis et al.17 Apo A-I M Levels and Antibodies to Apo A-I M The circulating level of apo A-I M was determined by an ELISA at Pharmacia Therapeutics. The ELISA uses two different mouse monoclonal antibodies (MAbs) developed against recombinant apo A-I M. The first MAb was used to coat the microtiter wells. Standard recombinant apo A-I M and appropriate dilutions of the serum samples were incubated. Bound apo A-I M was detected with the other MAb, which was biotinylated. The plate was developed using alkaline phosphatase, and the absorbance was read at 405 nm.
The presence of antibodies to apo A-I M was determined by a radioimmunoassay at Pharmacia Therapeutics. Serial dilutions of serum samples were incubated with ilslabeled plasma apo A-I M. The antibody-antigen complex was precipitated with a commercial anti-rabbit cellulose suspension (SAC-CEL, IDS Ltd) and measured in a gamma counter.
Immunohistochemistry
The semithin (10-,um) sections were mounted on Superfrost glass slides, rinsed in PBS, and incubated with blocking serum for 1 hour. The sections were washed three times in PBS, permeabilized by transfer to PBS/0.2% Triton X-100 for 5 minutes, rinsed in PBS, and incubated with PBS/1.5% blocking serum for 30 minutes. Excess blocking serum was blotted from the coverslips, and the sections were incubated with antibodies against macrophages (RAM 11) (Dako Corp) or smooth muscle-specific a-actin (HHF 35) (Dako Corp) for 18 hours at room temperature in a humidifying chamber. Controls included an irrelevant primary antibody as well as omission of the primary antibody. After being washed three times in PBS, the sections were incubated with biotinylated anti-mouse IgG for 60 minutes, washed three times in PBS, and stained with avidin/biotinylated alkaline phosphatase for 60 minutes. The sections were finally incubated with a solution of the alkaline phosphatase substrate for 30 minutes in the dark and counterstained with hematoxylin.
Morphometric Analysis
Ten-millimeter-thick sections of iliac and femoral arteries, taken at predetermined levels (proximal, mid, and distal), were cut at least 1 mm apart and stained with hematoxylin or by immunohistochemistry as described above and examined under microscopy. Total intimal area (area within the internal elastic lamina minus the luminal area) and the medial area (area between the internal elastic lamina and the external elastic lamina) were determined using the oPTiiAB 2.03 imageanalysis program (Graftek) on a Macintosh Ilci computer. 
Results

Blood and Aortic Tissue Cholesterol Levels
The three groups of animals showed no significant changes in body weight during the course of the study and did not differ significantly in their plasma levels of total and HDL cholesterol (Table) . The The mean intima-to-media ratio in animals receiving no treatment was 2.1+0.1. Compared with no treatment, the carrier alone resulted in a 28% reduction in this ratio to 1.5+±0.5 (P=NS), whereas treatment with apo A-I M resulted in a 67% reduction to 0.7±0.2 (P<.002). Compared with the carrier alone, apo A-I M reduced this ratio by 53% (P<.002).
Intimal Macrophage Content
Microscopic examination revealed the presence of macrophages in the media as well as the neointima (Fig  2) . In the media, the macrophages were present in areas of cellular degeneration. The 
